14 citations
,
November 2018 in “Journal of drug delivery and therapeutics” Ethosomes are effective, safe carriers for delivering drugs through the skin.
1 citations
,
August 2019 in “Chinese Medical Journal” A man developed facial skin lesions after a stem cell transplant, which improved with specific treatments.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
May 2009 in “OPAL (Open@LaTrobe) (La Trobe University)” Suppressing the HGPS mutation may improve symptoms and suggest reversibility.
November 2024 in “Rheumatology Advances in Practice” Rheumatology clinics should always provide preconception counseling for women on DMARDs.
1 citations
,
August 1983 in “PubMed” CVP therapy showed moderate success in treating advanced non-Hodgkin's lymphoma, but more intensive treatment is needed for better outcomes.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
A man with a rare lung-focused form of hypereosinophilic syndrome improved with steroid treatment.
July 2026 in “Theranostics” A new nanocage system protects hair cells and reduces hearing loss effectively.
The protein's size was reduced, but more work is needed to confirm its function.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
September 2022 in “European Journal of Dermatology” Gene sequencing is essential for diagnosing Junctional epidermolysis bullosa.
1 citations
,
January 2012 in “Médecine et Maladies Infectieuses” The man's symptoms improved significantly after penicillin treatment for syphilis.
1 citations
,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” The study found that Tourette Syndrome may be linked to certain immune system processes and synaptic signaling.
1 citations
,
December 2024 in “Archives of Iranian Medicine” Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
March 2025 in “Scientific Reports” Menthol-based microemulsions improve skin delivery of finasteride and silodosin.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
1 citations
,
March 2023 in “Journal of the American College of Cardiology”
June 2026 in “Acta Pharmacologica Sinica” Improving PROTAC delivery systems can enhance their effectiveness and speed up their use in medicine.
December 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” Montelukast is linked to increased risks of suicidal thoughts and depression.
8 citations
,
June 2004 in “Journal of Investigative Dermatology” Certain peptides can prevent hair loss in young rats caused by a cancer drug.
COVID-19 vaccines are generally safe for people with lupus, though some may experience mild flare symptoms.
13 citations
,
May 2019 in “Cancer Prevention Research” Grape seed extract may safely and effectively help prevent lung cancer.
May 2021 in “Biomedical Journal of Indonesia” Lupus hepatitis can affect male SLE patients and is treatable with specific medications.
Optimized liposomes can improve drug delivery and effectiveness.
January 2018 in “Hair transplant forum international” Naltrexone shows promise as a safe treatment for a type of hair loss called lichen planopilaris.
48 citations
,
February 2016 in “Scientific Reports” Researchers created rat liver stem cells that could help repair liver failure in rats and may be useful for studying human liver diseases.
5 citations
,
August 2020 in “Stem Cell Research & Therapy” Using fat-derived stem cells with the drug meglumine antimoniate can help control skin disease and reduce parasites in mice with leishmaniasis.
38 citations
,
June 2015 in “Expert Opinion on Therapeutic Targets” Blocking the prolactin receptor might help treat various diseases, but more research is needed.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.